Rybelsus and Weight Loss: Why It's Licensed for Diabetes, Not Obesity

Rybelsus is a once-daily semaglutide tablet licensed in the UK only for adults with type 2 diabetes, to help control blood glucose. It is not licensed for weight loss. People with diabetes often lose some weight on it, but the doses are lower than those used for weight management, and the weight loss in diabetes trials was modest. The oral semaglutide tablet licensed for weight management in the UK is a separate product, Wegovy tablets, authorised by the MHRA in June 2026. This guide explains why the two exist, what the evidence shows and why the distinction matters.

What Rybelsus is

Rybelsus, made by Novo Nordisk, was the first GLP-1 receptor agonist available as a tablet. It contains semaglutide, the same active ingredient as the injections Ozempic (for type 2 diabetes) and Wegovy (for weight management). It was authorised in Europe and the UK in 2020 and has been used widely in NHS diabetes care.

Its licensed use is to improve blood glucose control in adults with insufficiently controlled type 2 diabetes, alongside diet and exercise. It can be used on its own when metformin is unsuitable, or with other glucose-lowering medicines. That is the whole of its UK licence. You can check the current wording in the Rybelsus Summary of Product Characteristics (SmPC) on medicines.org.uk.

For a wider look at how the different semaglutide brands fit together, see semaglutide in the UK: Wegovy, Ozempic and Rybelsus explained.

How a peptide gets through the stomach

Semaglutide is a peptide, which would normally be destroyed in the stomach. Rybelsus combines it with an absorption enhancer called SNAC (salcaprozate sodium). SNAC creates a small zone of raised pH around the dissolving tablet and helps semaglutide cross the stomach lining. Only a small fraction of each dose is absorbed, which is why tablet doses are measured in several milligrams while weekly injection doses are under a few milligrams.

This mechanism also explains the strict instructions. Food, drinks or other tablets in the stomach interfere with SNAC and can sharply reduce absorption.

The new Rybelsus formulation

In 2025, a reformulated version of Rybelsus with improved absorption replaced the original tablets in the UK. Because more semaglutide is absorbed from each tablet, the new strengths are lower in milligrams but designed to give equivalent exposure.

NHS medicines bulletins in 2025 warned about the risk of errors while both versions were on the market, because the numbers are not interchangeable. Taking two 4mg new-formulation tablets is not the same as one 7mg original tablet, for example. If you take Rybelsus, check the strength on your pack and follow the instructions from your prescriber and pharmacist.

Why Rybelsus is not licensed for weight loss

A licence covers a specific use

In the UK, a medicine's marketing authorisation, granted by the MHRA, specifies exactly what it is approved to treat, at what doses and in whom. The manufacturer must provide trial evidence for each use. Rybelsus was developed and tested in people with type 2 diabetes, in the PIONEER trial programme. Novo Nordisk did not apply for a weight-management licence for Rybelsus at its diabetes doses.

Instead, the company ran a separate trial programme, OASIS, testing higher doses of oral semaglutide in people with overweight or obesity. That led to a different product: Wegovy tablets.

The doses are lower

The Rybelsus doses were chosen to control blood glucose with acceptable tolerability. Weight loss with GLP-1 medicines tends to increase with dose, and the highest Rybelsus dose provides lower semaglutide exposure than the weight-management doses studied in OASIS. In short, Rybelsus is not "Wegovy in a tablet". It is semaglutide at a dose designed for a different job.

Weight loss in diabetes trials was modest

Across the PIONEER trials, people with type 2 diabetes taking the highest original Rybelsus dose (14mg) typically lost a few kilograms on average over six months to a year, which was more than placebo and several comparator diabetes medicines, but well short of the weight loss seen with weight-management doses.

Part of the reason is the population. People with type 2 diabetes generally lose less weight on GLP-1 medicines than people without diabetes, even at the same dose. This pattern is seen with semaglutide injections and with tirzepatide.

Rybelsus compared with Wegovy tablets

The overlap in strengths between the two products is a point of caution. Even where the milligram figures look the same, the products have different licences and packaging, and the dose schedule for weight management continues to a much higher level. Always check the SmPC for each product and follow your prescriber's instructions.

For a fuller explanation of the weight-management tablet, see our oral semaglutide guide.

What the evidence shows

PIONEER: Rybelsus in type 2 diabetes

The PIONEER programme included around ten phase 3 trials. They compared oral semaglutide with placebo and with other diabetes medicines, including sitagliptin, empagliflozin and liraglutide injections. In general, Rybelsus lowered HbA1c (a measure of average blood glucose) effectively and led to modest weight loss.

PIONEER 6, published in the New England Journal of Medicine in 2019, was a cardiovascular safety trial. It showed that oral semaglutide did not increase the risk of major cardiovascular events in people with type 2 diabetes at high cardiovascular risk, which was the main question it was designed to answer.

SOUL: cardiovascular outcomes

The SOUL trial, published in the New England Journal of Medicine in 2025, studied oral semaglutide in people with type 2 diabetes and established cardiovascular disease, chronic kidney disease or both. It reported a reduction in major adverse cardiovascular events compared with placebo. These results relate to people with diabetes; they do not show that Rybelsus is a weight-loss treatment, and how they apply to individuals is a matter for their clinician.

OASIS: oral semaglutide for weight management

The OASIS trials tested oral semaglutide in people with overweight or obesity.

• OASIS 1 (The Lancet, 2023) used a 50mg daily dose and reported average weight loss of about 15% at 68 weeks, compared with about 2% on placebo. This dose is not the one licensed in the UK.
• OASIS 4 (New England Journal of Medicine, 2025) used a 25mg daily dose and reported average weight loss of about 14% at 64 weeks, compared with about 2% on placebo, rising to about 17% among people who took the medicine as directed.

These findings underpinned the UK licence for Wegovy tablets. For comparison, the STEP 1 trial of weekly semaglutide 2.4mg injections reported average weight loss of about 15% at 68 weeks.

What about off-label use?

"Off-label" means prescribing a licensed medicine for a purpose, dose or group not covered by its licence. It is legal in the UK, but the General Medical Council expects prescribers to be satisfied that it serves the patient's needs better than licensed options, to have sufficient evidence of safety and efficacy, and to explain the situation clearly to the patient.

Before 2026, some people asked whether Rybelsus could be used for weight loss because there was no licensed GLP-1 tablet for obesity. That situation has changed. With Wegovy tablets and Foundayo (orforglipron) now authorised for weight management in the UK, alongside weekly injections, it is hard to see a prescriber justifying Rybelsus off-label for weight loss in someone without diabetes. Regulated online pharmacies generally prescribe weight-management medicines within their licensed indications.

There is also a supply consideration. During GLP-1 shortages in 2023 and 2024, UK health authorities asked prescribers to avoid off-label use of diabetes-licensed GLP-1 medicines for weight loss, to protect supply for people with diabetes. Our guide to Ozempic vs Wegovy explains the same principle for the injections.

If you have type 2 diabetes and want to lose weight

Many people with type 2 diabetes are also living with overweight or obesity, and weight loss can improve blood glucose control. If this applies to you, the options might include:

• Rybelsus or another diabetes medicine chosen by your diabetes team, with weight loss as a welcome effect.
• A weight-management licensed medicine, such as Mounjaro, Wegovy injections or Wegovy tablets, where you meet the criteria. Tirzepatide and semaglutide are both licensed for diabetes and for weight management under different brand names.
• NHS weight-management services, including the NHS Digital Weight Management Programme and, where eligible, specialist services.

You should not combine two GLP-1 medicines, for example Rybelsus with Wegovy or Mounjaro. A prescriber will decide which single medicine is appropriate and adjust other diabetes treatments if needed, because the risk of low blood sugar rises when GLP-1 medicines are combined with insulin or sulfonylureas.

Our guides to who can get weight loss injections and Wegovy on the NHS explain eligibility.

How to take Rybelsus correctly

The patient information leaflet gives the full instructions. In summary:

1. Take the tablet when you wake, on an empty stomach.
2. Swallow it whole with a small sip of plain water. The leaflet gives the maximum volume.
3. Do not split, crush or chew it.
4. Wait at least 30 minutes before eating, drinking or taking other oral medicines.
5. If you miss a dose, skip it and take the next one the following day. Do not take two doses at once.

Doses are increased gradually, starting with the lowest strength for a month, to reduce gastrointestinal side effects.

Side effects of Rybelsus

The side effects are similar to other GLP-1 medicines. The most common are gastrointestinal:

• Nausea
• Diarrhoea
• Vomiting
• Constipation, abdominal pain, indigestion and reflux
• Reduced appetite

These tend to be worst early in treatment and after dose increases. Less common but more serious risks include pancreatitis, gallbladder problems and dehydration leading to kidney problems. Low blood sugar can occur when Rybelsus is combined with insulin or sulfonylureas. People with diabetic retinopathy should be monitored, as rapid improvements in blood glucose have been associated with temporary worsening of retinopathy with semaglutide.

For more detail on tablet side effects, see oral GLP-1 side effects.

Where Rybelsus fits in NHS diabetes care

In the NHS, type 2 diabetes treatment follows NICE guideline NG28 and local prescribing guidance. Metformin is usually the first medicine, and other options, including SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, GLP-1 medicines and insulin, are added depending on blood glucose, cardiovascular and kidney risk, weight and individual circumstances. The exact position of GLP-1 medicines in the pathway has been updated over time and can vary locally, so your diabetes team is the right source of advice on where Rybelsus might fit for you.

Within that pathway, Rybelsus offers an alternative for people with diabetes who would benefit from a GLP-1 medicine but prefer not to inject. Its weight-reducing effect is one reason it may be chosen for someone with diabetes who is also living with overweight, but the decision is driven by diabetes control and overall risk, not by weight alone.

Tablet or injection in diabetes?

People with type 2 diabetes who are considering a GLP-1 medicine may be offered a choice between a weekly injection, such as Ozempic (semaglutide) or Mounjaro (tirzepatide, which is also licensed for diabetes), and a daily tablet such as Rybelsus. The considerations are similar to those in weight management:

• Routine. Rybelsus must be taken daily on an empty stomach with a waiting period. Weekly injections avoid this but involve a needle.
• Effect size. Weekly injectable semaglutide and tirzepatide have generally produced larger reductions in HbA1c and weight in trials than oral semaglutide at diabetes doses, although results depend on dose and trial.
• Other medicines. People who take several morning medicines, such as levothyroxine, may find the Rybelsus timing rules difficult.

Our comparison of oral and injectable GLP-1s explores these trade-offs in more depth.

How the two semaglutide tablets came about

It can seem confusing that the same company makes two semaglutide tablets with different names. The explanation lies in how medicines are developed and licensed.

When oral semaglutide was first developed, the target was type 2 diabetes, where GLP-1 injections were already established. The PIONEER trials established doses that controlled blood glucose effectively, and Rybelsus was licensed on that basis.

Meanwhile, the STEP trials showed that weekly semaglutide at 2.4mg, a higher dose than Ozempic, produced substantial weight loss in people with obesity. That led to Wegovy injections, licensed separately for weight management. The same logic then applied to tablets: the OASIS trials tested higher oral doses for weight management, leading to Wegovy tablets.

Keeping the products separate means each has clear instructions, packaging and dose schedules for its licensed use. It also helps protect supply for people with diabetes, which was a concern during the GLP-1 shortages of 2023 and 2024.

Questions to ask your prescriber

If you are considering an oral GLP-1 medicine, these questions may help structure the conversation:

• Do I meet the criteria for a weight-management medicine, a diabetes medicine, or both?
• Would a tablet or an injection suit my routine and other medicines better?
• How would my other diabetes medicines need to change, if at all?
• What side effects should I expect, and what should I do if they are troublesome?
• How long would I expect to take this medicine, and what happens if I stop?
• How will my progress be monitored?

Myths and misunderstandings

"Rybelsus is just a cheaper Wegovy." It is a different product with a different licence and lower doses. Cost comparisons between medicines with different licences are not meaningful for choosing a weight-management treatment.

"If I take two Rybelsus tablets I'll get the Wegovy dose." No. Taking more than one tablet at a time is not how the product is designed and may reduce absorption. Never change your dose without advice.

"Rybelsus is safer than an injection." The side-effect profile is similar to injectable semaglutide. Tablets avoid injection-site reactions but not the gastrointestinal effects.

"Any semaglutide tablet sold online is Rybelsus or Wegovy." Be cautious of tablets, drops or sprays claiming to contain semaglutide that are sold without a prescription. These are not licensed medicines. Our guide to fake and unlicensed weight loss jabs explains the risks.

Understanding costs

We do not quote prices in our guides. Rybelsus prescribed for diabetes on the NHS is covered by standard prescription charges in England, or is free in Scotland, Wales and Northern Ireland and for people with medical exemption certificates. Private costs for weight-management medicines, including Wegovy tablets, depend on the medicine, dose, provider and what support is included. For current information, see our price comparison.

When to speak to a professional

Speak to your GP, diabetes nurse, pharmacist or prescriber if:

• You take Rybelsus and want to know whether a weight-management medicine would be more suitable
• You are unsure which Rybelsus strength you have after the formulation change
• You take other diabetes medicines and are considering any GLP-1 treatment
• You are pregnant, planning pregnancy or breastfeeding
• You have a history of pancreatitis, gallbladder disease, kidney problems, diabetic eye disease, or a personal or family history of medullary thyroid cancer

Seek urgent medical help through NHS 111, or call 999 in an emergency, if you have:

• Severe, persistent abdominal pain that may spread to the back, with or without vomiting
• Repeated vomiting or diarrhoea that stops you keeping fluids down, or signs of dehydration
• Symptoms of low blood sugar that do not improve with treatment, such as confusion, shaking or sweating
• Signs of a severe allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing
• Sudden changes in your vision

You can report suspected side effects through the MHRA Yellow Card scheme. For more on all the tablet options, visit our oral GLP-1 hub.